Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) [Phase 1, Phase 2]

View source ↗

Summary

This update reports the Phase 1/2 ZUMA-3 trial results for Brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory B-precursor acute lymphoblasti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• Brexucabtagene autoleucel (KTE-X19) (brexucabtagene autoleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-11-29